Need to stop metformin before imaging?

Metformin has been used clinically for more than

Metformin has been used clinically for more than

1.

1.

Heart failure is the final stage of the development of various heart diseases

2018 Nian ADA diabetes guidelines recommend, if normal renal function, metformin can be used in patients with chronic stable heart failure

2.

Metformin was discontinued before the patient's angiography or general anesthesia

Moderate renal insufficiency [ the eGFR is 45 ~ 59 ml / ( min ·.

3.

Metformin has a direct or indirect cardiovascular protective effect by effectively improving the IR of diabetic and non-diabetic patients and reducing the basal and post-load insulin levels

Metformin has been proven to lower blood sugar, improve NAFLD and IR (especially liver and muscle), reduce weight, improve blood lipids and anticoagulation

Of course, it is worth noting that if diabetic patients have high blood pressure or hyperlipidemia, metformin can be used for hypoglycemic treatment, but you must not stop antihypertensive drugs or lipid-lowering drugs because metformin helps lower blood pressure and lipids.

4.

At present, there are mainly single-component metformin ordinary tablets ( 250 mg/ tablet, 500 mg/ tablet or 850 mg/ tablet), metformin sustained-release tablets or capsules ( 500 mg/ tablet or 500 mg/ capsule), and metformin enteric-coated tablets at home and abroad .

Agent metformin amount adjustment principle " small doses starting, gradually increase the volume "

5.
What are the contraindications for metformin? 5.
What are the contraindications for metformin?

Although numerous guidelines unanimous recommendation of metformin for 2 antidiabetic drug of choice for the treatment of patients with diabetes, but some people still do not apply:

Although numerous guidelines unanimous recommendation of metformin for 2 antidiabetic drug of choice for the treatment of patients with diabetes, but some people still do not apply:

1 ) Moderate ( grade 3b ) and severe renal failure or renal insufficiency [ CrCl ＜45 ml/min or eGFR ＜45 ml/ ( min∙1.
73 m2 )];

1 ) Moderate ( grade 3b ) and severe renal failure or renal insufficiency [ CrCl ＜45 ml/min or eGFR ＜45 ml/ ( min∙1.
73 m2 )];

2 ) tissue hypoxia may cause diseases (in particular acute or chronic disease worsening), as decompensated heart failure, respiratory failure, a recent development as myocardial infarction, shock;

2 ) tissue hypoxia may cause diseases (in particular acute or chronic disease worsening), as decompensated heart failure, respiratory failure, a recent development as myocardial infarction, shock;

3 ) severe infection and trauma, surgical big surgery, and hypotension;

3 ) severe infection and trauma, surgical big surgery, and hypotension;

4 ) Those who are known to be allergic to metformin hydrochloride;

4 ) Those who are known to be allergic to metformin hydrochloride;

5 ) Acute or chronic metabolic acidosis, including DKA with or without coma ( DKA requires insulin treatment);

5 ) Acute or chronic metabolic acidosis, including DKA with or without coma ( DKA requires insulin treatment);

6 ) Alcoholics;

6 ) Alcoholics;

7 ) connected by intravascular injection iodinated contrast agent, could temporarily stop using;

7 ) connected by intravascular injection iodinated contrast agent, could temporarily stop using;

8 ) Those who have not corrected vitamin B12 and folic acid deficiency
.

8 ) Those who have not corrected vitamin B12 and folic acid deficiency
.

6.
What are the adverse reactions of metformin?

6.
What are the adverse reactions of metformin? 6.
What are the adverse reactions of metformin?

Metformin common adverse reactions include diarrhea, nausea, vomiting, bloating, fatigue, digestion is not good, abdominal discomfort and headache, occur early in treatment, most patients can tolerate
.
With the extension of treatment time, the above-mentioned adverse reactions can basically disappear
.

Metformin common adverse reactions include diarrhea, nausea, vomiting, bloating, fatigue, digestion is not good, abdominal discomfort and headache, occur early in treatment, most patients can tolerate
.
With the extension of treatment time, the above-mentioned adverse reactions can basically disappear
.

Start with a small dose, gradually increase the dose, and adjust the dose at the right time.
The non-sustained-release preparation is taken with meals in divided doses, or changed to a 1 time /d sustained-release preparation, which can reduce gastrointestinal reactions.
Metformin itself has no hepatic or nephrotoxicity
.

Start with a small dose, gradually increase the dose, and adjust the dose at the right time.
The non-sustained-release preparation is taken with meals in divided doses, or changed to a 1 time /d sustained-release preparation, which can reduce gastrointestinal reactions.
Metformin itself has no hepatic or nephrotoxicity
.

references

references

1.
Yoshiaki mother , JI Li-nong , Li Chunlin , and so on .
Metformin Clinical application of expert consensus (2018 edition ) [J].
Chinese Journal of Diabetes , 2019, 027 (003): 161-173.

1.
Yoshiaki mother , JI Li-nong , Li Chunlin , and so on .
Metformin Clinical application of expert consensus (2018 edition ) [J].
Chinese Journal of Diabetes , 2019, 027 (003): 161-173.

2.
Wang Jian , Liu Guangzhong , Bai Nan , et al .
The role of metformin in the prevention and treatment of cardiovascular diseases [J] .
International Journal of Cardiovascular Diseases , 48(1):5.

2.
Wang Jian , Liu Guangzhong , Bai Nan , et al .
The role of metformin in the prevention and treatment of cardiovascular diseases [J] .
International Journal of Cardiovascular Diseases , 48(1):5.


Leave a message here